It now costs an average of $2bn to develop a new drug, up from $1.2bn in 2010. One theory is that the easier discoveries have already been made. As medicines become more personalised, the returns per drug may be squeezed because fixed development costs are spread across a smaller pool of potential patients. Either way, firms may have fewer incentives to innovate.
March 22, 2018